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Abstract
Background: Treatment of primary gastric diffuse large B-cell lymphoma is still controversial. The
treatment of localized disease was based on surgery alone, or followed by chemotherapy and/or
radiotherapy. High-grade gastric lymphomas are generally believed to be Helicobacter pylori (HP)-
independent growing tumors. However a few cases of regression of high-grade gastric lymphomas
after the cure of Helicobacter pylori infection had been described.
Case presentation: We report here a case with primary diffuse large B-cell lymphoma that
showed a complete pathologic remission after HP eradication and we reviewed the literature. A
computerized literature reach through Medline, Cancerlit and Embase were performed, applying
the words: high grade gastric lymphoma, or diffuse large B cell, MALT gastric lymphoma, DLBCLL
(MALT) lymphoma and Helicobacter. Articles and abstracts were also identified by back-
referencing from original and relevant papers. Selected for the present review were papers
published in English before January 2007.
Conclusion: Forty two cases of primary high grade gastric lymphoma that regressed with anti HP
treatment were found. There were anedoctal cases reported and patients belonging to prospective
studies; four trials studied the effect of eradication of Helicobacter pylori as first line therapy in high
grade gastric lymphoma: 22 of a total of 38 enrolled patients obtained complete remission. Depth
of gastric wall infiltration and clinical stage were important factors to predict the response to
antibiotic therapy. Our case and the review of the literature show that high-grade transformation
is not necessarily associated with the loss HP dependence. In early stage, for high-grade B-cell HP-
positive gastric lymphomas, given the limited toxicity of anti-HP therapy, this treatment may be
considered as one of the first line treatment options.
Background
Helicobacter pylori (HP) infection plays an important role
in the development and growth of gastric mucosa-associ-
ated lymphoid tissue (MALT) lymphomas [1,2]. Eradica-
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tumor regression in 77% of patients with low-grade gas-
tric MALT lymphoma [3].
It has been demonstrated by laboratory and clinical stud-
ies that primary gastric large B cell MALT lymphomas are
transformed, antigen independent, autonomously grow-
ing tumors that are unlikely to respond to eradication
therapy of the HP infection. An in vitro study by Hussell et
al [4] showed that tumor cells from high grade gastric lym-
phoma did not respond to a co-stimulation of autologous
T cells and lysate of a specific HP strain, as low grade gas-
tric MALT lymphoma cells did. In addition, these results
are also supported by the finding that most cases of anti-
biotics-resistant low grade MALT lymphoma contained an
high grade component in the deeper layer of the gastric
wall in their gastrectomy specimen [5,6].
However anedoctal cases of primary gastric large B-cell
lymphoma that responded to antibiotic therapy had been
described and, more recently, Chen et al [7] reported in a
prospective study the disappearance of primary gastric
large B-cell lymphoma at gastroscopy examination in 14
of 22 patients (64%) after HP eradication therapy.
We report here a patient with diffuse large B cell lym-
phoma of the stomach, that achieved a complete patho-
logic remission after anti HP therapy and a detailed review
of literature is also presented.
Case presentation
In May 2003, a 43-year-old man was admitted for epigas-
tric pain of two months duration and weight loss (more
than 10% of the body weight). Clinical examination was
unremarkable and laboratory data were within normal
values; only a mild hypochromic anemia was disclosed
(Hb 12.4 g/dl).
A gastroscopy was performed and revealed an ulcerative
lesion in the gastric antrum ranging 3 cm in diameter.
Biopsies established the diagnosis of diffuse large B cell
lymphoma (DLBCL) of the stomach and Helicobacter
pylori was identified in the mucosa. The previously
reported diagnostic criteria for gastric diffuse large B-cell
lymphoma were used [7,8] (Figure 1).
Endoscopic ultrasonography (EUS) showed a hemicir-
cumferencial thickness of the anterior gastric wall, which
was infiltrated until to the serosa. Staging was completed
with neck, chest and abdominal computed tomography
and with bone marrow biopsy. There were not other lym-
phoma-deposits outside the stomach, and a clinical stage
E I2 was established.
The patient refused chemotherapy and a surgical treat-
ment was then planned. Waiting this treatment, the
patient underwent an HP eradication therapy. He received
a triple therapy with omeprazole (20 mg twice a day),
amoxicillin (1 g twice a day) and clarithromycin (500 mg
twice a day) for seven days, and after that omeprazole (20
mg every day) for other 21 days.
Prior to surgery, the patient underwent repeat gastroscopy
(a month later) that showed a clear improvement of the
ulcerative lesion of the gastric antrum and biopsies
showed a complete disappearance of the lymphoma (Fig-
ure 2).
The patient was informed of the good results from anti HP
therapy but he preferred to undergo to subtotal gastric
resection. The histological examination revealed complete
remission of the lymphoma and absence of Helicobacter
pylori. He did not receive additional treatment and is in
continuous complete remission after 42 months.
Review of literature
We selected all cases reported with primary gastric large B-
cell lymphoma treated with anti HP treatment and all
cases of primary gastric large B-cell lymphoma treated in
prospective studies with anti HP-therapy. According to the
WHO classification, low grade MALT lymphoma with
focal high grade component constituted by "solid or
sheet-like proliferations of transformed cells" were
included as diffuse large B-cell lymphoma [8].
Histology before triple therapy shows antral gastric mucosa exhibiting intersti ial infiltrate compo ed of arge sized cen-troblast-like lymphoid cells (inset), with occasional ly ph ep-itheli l lesions (arrows) (Giemsa, inset H&E ×200)Figure 1
Histology before triple therapy shows antral gastric 
mucosa exhibiting interstitial infiltrate composed of 
large sized centroblast-like lymphoid cells (inset), 
with occasional lymphoepithelial lesions (arrows) 
(Giemsa, inset H&E ×200).Page 2 of 7
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by Musshoff  and  Schmidt-Vollmer, Ann Arbor Classifica-
tion [9] for extranodal lymphomas. Response rate were
analyzed only if patients were included in prospective
studies.
Results
A total of 61 patients, including the present case, with pri-
mary gastric large B-cell lymphoma were treated with anti
HP treatment [7,10-25] and 42 of them showed a com-
plete response. There were anecdotal cases reported and
patients belonging to prospective studies. Four trials stud-
ied the effect of eradication of Helicobacter pylori as first
line therapy in gastric high grade gastric lymphoma: 22 of
a total of 38 (57.9%) enrolled patients obtained complete
remission. Data of the 42 responsive patients are reported
in Table 1.
Different schedules of eradication treatment were used
and were based on a proton pump inhibitor (omeprazole,
lansoprazole, or rabeprazole) together with a combina-
tion of antibiotics (clarithromycin, amoxicillin, and/or
metronidazole). Forty-two of 61 patients obtained a com-
plete remission of the lymphoma. In two patients there
was gastric complete remission (despite of persistence of
Helicobacter pylori in one patient) with remaining nodal
disease. In one patient, large B cells disappeared, but areas
of MALT lymphoma and nodal disease persisted. The
patient with Burkitt-like lymphoma, obtained a complete
remission.
Two patients were affected by AIDS [15,18]. In one of
these patients, the eradication treatment was started
together with antiretroviral therapy (stavudine, lamivu-
dine and indinavir). Both patients obtained, almost ini-
tially, a complete remission.
The median time to remission of lymphoma, calculated
on data available from 31 patients, was 8 weeks from the
end of the eradication treatment. The median time to
complete response reported by Chen et al., [7] was 9.6
months (range 0.0 to 20.4) for DLBCL (MALT) with low-
grade predominant and 5.5 months for DLBCL (MALT)
predominant.
Initial or complete regression of lymphoma was evident at
the first gastroscopic examination (in most cases 4–8
weeks after the end of eradication treatment) in the major-
ity of patients; only in one patient, there was a progression
of disease after an initial partial response [22].
Four patients including present case underwent subtotal
or total gastrectomy, after endoscopic confirmation that
Helicobacter pylori infection was cured and lymphoma
regressed [15,22].
Other patients in complete remission didn't undergo fur-
ther treatment, except one patient with AIDS who
relapsed after 6 months and needed chemotherapy. This is
the only one relapse described. Two patients, in partial
remission after eradication treatment, gained complete
regression of lymphoma after chemotherapy [15,22].
Because of the advanced age, additional chemotherapy
was postponed in a patient; "wait and watch" follow-up
was chosen for him [15].
Table 1: Clinico-pathologic characteristics of 42 patients with 
high-grade B-cell gastric lymphoma responsive to eradication 
therapy
Age, median range year 59 (21–85)
Sex, Male/female 20/20, 2 not reported
Location of tumor (s), n (%)
Antrum 15 (35.71)
Middle and/or lower body 17 (40.47)
More than two components 10 (23.80)
stage 30 (71.4) EI1
6 (14.3) EI2
3 (7.1) EII1
1 (2.4) EIII
2 not reported
Deaph of gastric wall involvement n(%)
Submucose or above 21 (50)
Muscolaris propria or beyond 12 (28.57)
9 not reported
Histology after triple therapy shows antral gastric mucosa w th sparse lymphoplasmacellular interstitial infiltrate, with-out evidence of lym ho tou  cell (H&E ×200)Figure 2
Histology after triple therapy shows antral gastric 
mucosa with sparse lymphoplasmacellular interstitial 
infiltrate, without evidence of lymphomatous cells 
(H&E ×200).Page 3 of 7
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longer period of follow-up was reported in the series of
Chen et al., [7]: all the 14 DLBCL (MALT) patients with CR
remained relapse-free after a median follow-up of 63
months.
Information about genetics of large B cells didn't express
bcl-6 and p53; in the patient with Burkitt-like lymphoma,
malignant cells expressed bcl-6 and p53; in the with
Burkitt-like lymphoma, malignant cells expressed bcl-6
and not bcl-2; in two patients there were not alterations of
p53 and k-ras genes and microsatellite instability [16].
In 20 patients, tumor response was unexpected, but in 22
cases it was obtained in prospective trials. Chen et al., [7]
reported 14 cases, Nakamura et al., [10] 5 cases, Hiyama et
al., [16] 2 cases and Alpen et al., [22] 1 case.
Discussion
In the present case, eradication of HP infection obtained
with a short course of antibiotic therapy resulted in a com-
plete pathologic remission of a diffuse large B cell lym-
phoma of the stomach. This complete regression of the
disease was confirmed not only by gastroscopy and biop-
sies but also by gastrectomy.
This finding confirms one more time that large B cell HP-
positive gastric lymphomas are not necessarily associated
with loss of HP dependence. Until few years ago, large B
cell gastric lymphoma was considered independent of
Helicobacter pylori stimulation. This assertion was sup-
ported by in vitro and in vivo results.
A study by Hussell et al., [4] showed that cells of a large B
cell gastric lymphoma did not proliferate in vitro in
response to Helicobacter pylori, as MALT lymphoma cells
did.
In vivo confirmation came from the fact that a number of
cases of antibiotic-resistant MALT lymphoma contained
large B cells in deep layers of the stomach and these cells
were thought responsible for absent response of these
tumors [5,6]. Boot et al., [26] concluded that antimicro-
bial treatment should not be chosen as primary therapy
for high grade MALT Non Hodgkin lymphoma, but addi-
tional Helicobacter pylori eradication could play a part in
optimum treatment of an accompanying low grade com-
ponent.
In 1997, Rudolph et al., [11] described a patient affected
by DLBCL with areas of MALT lymphoma that responded
to antimicrobial therapy. After few months, Seymour et
al., [12] reported the case of a 73 year-old woman with a
DLBCL and Helicobacter pylori associated chronic active
gastritis; she refused chemotherapy and received only
eradication treatment with an unexpected tumor remis-
sion. These two cases were the first published cases of
regression of large B cell lymphoma after eradication ther-
apy. Afterwards analogous surprising situations were
reported.
Morgner et al., [15], collecting 8 cases of lymphoma
regression, underscored the possible role of antimicrobial
therapy in the treatment of gastric large B cell lymphoma.
When this approach was studied as first line therapy for
gastric large B cell lymphoma in clinical trial, encouraging
results were obtained: there was a complete remission in
64% of cases (14 of 22) for Chen et al., [7], in 50% (2 of
4) for Hiyama et al., [16] and in 50% (5 of 10) for Naka-
mura et al., [10]. Alpen et al., [22] started a pilot-trial to
investigate the role of HP eradication therapy in early gas-
tric high-grade B-cell lymphoma prospectively. So far, two
patients were treated, both patients become HP-negative
after eradication therapy: one patient achieved CR. And
the second patient received only a partial remission of the
lymphoma. These studies present some limitations: as
they include few patients; patients enrolled by Chen et al.,
[7] and Hiyama et al., [16] are a well defined subgroup
characterized by clinical stage E I and presence of areas of
MALT lymphoma; clinical stage is not clear in patients
with high grade or low with focal high grade enrolled by
Nakamura et al., [10]. Alpen et al., [22] in their study
included patients with early high-grade gastric B-cell lym-
phoma at stage E I.
These authors paid attention to different prognostic fac-
tors. Hiyama et al., [16] focused on cytogenetic features,
but they did not find any suggestive factor. Two largest tri-
als indicated the depth of infiltration of tumor as the
determinant factor for the complete remission: 100% (7
of 7) of tumors limited to mucosa or submucosa versus
30% (3 of 10) of those infiltrating to or beyond muscola-
ris propria achieved a complete remission as reported by
Chen et al., [7]; for Nakamura et al., [10], 93% of all
tumors (high and low grade) limited to the mucosa versus
23% of those demonstrating deep invasion of the submu-
cosa or beyond obtained a complete remission.
In this review of the literature, age, sex, location of tumor
and the presence or absence of areas of MALT lymphoma
don't seem to influence the response of anti Helicobacter
therapy. Clinical stage and depth of tumor invasion are
the most important predictive factors of complete remis-
sion [27]. However it must be emphasized that locally-
advanced stages can respond to the eradication treatment
too. In some cases in stage beyond E I, there was a com-
plete response of DLBCL in terms of gastric localization,
but with persistent nodal disease[12,15]; surprisingly, in a
patient, MALT lymphoma was detected after eradicationPage 4 of 7
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peared[15].
Very little is reported about genetics of these tumors
[28,29]. According to the lymphoma MALT concept pro-
posed by Isaacson and Wright [30], there is a sequence of
events without solution of continuity from acquisition of
gastric MALT, in most cases because of a Helicobacter pylori
infection, to MALT lymphoma and large B cell lym-
phoma. There is consistent evidence for the clonal link
between the small cell tumor and the large cell tumor
[31]. This evolution is possible in t(11;18)(q21;q21) neg-
ative MALT lymphoma after the accumulation of some
genetic aberrations which progressively increase its
genetic instability [32]. t(11;18)(q21;q21) positive lym-
phoma does not transform itself and it does not accumu-
late genetic anomalies, but it has an aggressive course and
is resistant to Helicobacter pylori eradication [33]. There-
fore, two groups of DLBCL can be identified: one derives
from a t(11;18)(q21;q21) negative MALT lymphoma;
one, which contains less numerical genetic aberrations,
arises de novo [32]. Not all DLBCLs without areas of MALT
lymphoma arise de novo. The absence of the low grade
component could be due to sampling bias or to over-
growth by large cells [31]. It is unknown if DLBCLs
regressed after Helicobacter pylori eradication have a com-
mon genetic pattern and if cases without areas of MALT
lymphoma are transformed lymphomas or de novo lym-
phomas.
The gold standard of treatment of primary gastric DLBCL
is still controversial. The treatment of localized (stage EI
and EII) disease was based on surgery alone, or followed
by chemotherapy and/or radiotherapy, however recent
studies showed that clinical outcome of localized gastric
lymphoma treated by systemic chemotherapy alone was
similar to that treated by surgery followed by chemother-
apy in terms of tumor response, disease-free survival and
overall survival suggesting that surgery be reserved for
those with residual lymphoma after chemotherapy [34-
38].
According to this review, among patients with complete
remission obtained after eradication therapy, only one
patient, who was affected by HIV infection, relapsed.
These data suggest that after a complete remission, no
other treatment including gastrectomy might be neces-
sary, even if full thickness of gastric wall is infiltrated at
presentation.
In most cases of gastric MALT lymphoma remission is
achieved within 12 months after Helicobacter pylori eradi-
cation, but a late response of up to 45 months has been
described [39]. Among these 42 cases of primary gastric
large B cell lymphoma that obtained a complete remis-
sion after eradication treatment, the median time from
the end of the therapy to the demonstration of remission
was 8 weeks. If there were not signs of initial or complete
response at the first endoscopic control (4–6 weeks after
the end of eradication treatment), it was a contraindica-
tion to continue follow-up and an indication to conven-
tional treatment [7,10,22]. Alpen et al., [22] submitted
patients with only a partial response to chemotherapy/
radiotherapy two months after the end of eradication
therapy. Hiyama et al., [16] extended the follow-up to six
months from the end of eradication therapy, at that point
patients with partial or no response were treated with
chemotherapy.
In all cases that responded to eradication therapy, initial
or complete regression of lymphoma was evident at the
first endoscopic and histologic examination. Only in one
case, there was a disease progression, after an initial
response, at the second examination [22].
Conclusion
Our case reported here and the review of the literature
allow us to conclude that:
1. Complete remission was obtained after HP eradication
treatment in 42 of 61 patients with primary gastric HP
related DLBCL.
2. There is no marker that can predict if the tumor will
regress after antimicrobial therapy. However, depth of
gastric wall infiltration and clinical stage can strongly pre-
dict the probability of a complete remission, it must be
emphasized that complete remission was reached in anec-
dotal cases independently of these factors after anti HP
eradication.
From a practical point of view we suggest that all patients
with primary gastric DLBCL associated with Helicobacter
pylori infection a complete staging with endoscopic ultra-
sonography, computed tomographic imaging and bone
marrow biopsy should be carried out and the patients
should first be treated by anti HP treatment. An endo-
scopic revaluation 4–6 weeks after the eradication treat-
ment should be performed. These evolutions of
lymphoma can happen:
- No response or progression: patient must undergo to
surgery or other conventional treatment.
- Partial remission: lymphoma is probably responsive and
could obtain a complete remission; patient must be
strictly monitored to detect signs of progression or a com-
plete remission.Page 5 of 7
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but may not require further treatments.
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